Overview

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function. The study will also evaluate the safety and tolerability of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.